ELREXFIO treats adults with relapsed or refractory multiple myeloma who have already received at least 4 treatment regimens and their cancer has come back or did not respond to treatment. ELREXFIO is approved based on patient responses and durability of response.

ELREXFIO is an off-the-shelf BCMA-directed bispecific immunotherapy2.

2023年8月14日 · ELREXFIO is a subcutaneously delivered B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy that binds to BCMA on myeloma cells and CD3 on T-cells, bringing them together and activating the T-cells to kill myeloma cells.

elrexfio是一种双特异性b细胞成熟抗原(bcma)导向的cd3t细胞接合剂，用于治疗患有复发性或 难治性多发性骨髓瘤 的成年患者，这些患者之前至少接受过四种疗法，包括蛋白酶体抑制剂、免疫调节剂和 抗cd38单克隆抗体 。

2023年8月23日 · Elrexfio is used in adults who have relapsed or refractory multiple myeloma (RRMM) and have tried at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Elrexfio is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb).

2024年2月4日 · 2023年1月31日，中国国家药监局药品审评中心（CDE）网站显示，Elranatamab（Elrexfio）在国内申报上市，用于治疗既往接受过治疗的复发或难治性多发性骨髓瘤（R/R MM），有望为更多中国患者提供有效治疗选择，改善疾病控制率，并延长患者的生存期。

ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

2023年10月13日 · Elrexfio is a cancer medicine used to treat adults with multiple myeloma (a cancer of the bone marrow) when the cancer has come back (relapsed) and has not responded to treatment (refractory). It can be used in adults who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 ...

On August 14, 2023, the Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell...

ELREXFIO - U.S. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources for Healthcare professionals: https://www.elrexfiohcp.com